Confidence in Concept 2012 - Imperial

Lead Research Organisation: Imperial College London
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

publication icon
Buss NA (2015) Targeting the annexin 1-formyl peptide receptor 2/ALX pathway affords protection against bacterial LPS-induced pathologic changes in the murine adrenal cortex. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology

 
Description Oliver ICiC - JDRF Continuous Glucose Monitoring Roundtable
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
URL https://www.jdrf.org.uk/research/type-1-diabetes-research-roadmap
 
Description Wigneshweraraj - ICiC1 - Berlin
Geographic Reach Europe 
Policy Influence Type Participation in a guidance/advisory committee
Impact Contribution to defining the MRC/BBSRC AMR theme 4 call for applications at a workshop in Berlin.
 
Description Action Against Cancer grant
Amount £78,000 (GBP)
Organisation Action Against Cancer (AAC) 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2012 
End 06/2015
 
Description Action Medical Research Project Grant
Amount £188,536 (GBP)
Organisation Action Medical Research 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Asthma UK Innovations Award
Amount £46,540 (GBP)
Funding ID AUK-IG-2014-286 
Organisation Asthma + Lung UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2014 
End 03/2016
 
Description BBSRC NPIF Phd Studentship
Amount £0 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start  
 
Description BHF Clinical Research Training Fellowship
Amount £186,887 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2015 
End 12/2018
 
Description Biomedical research unit (BRU) funding
Amount £165,000 (GBP)
Organisation Royal Brompton & Harefield NHS Foundation Trust 
Department Respiratory Biomedical Research Unit
Sector Public
Country United Kingdom
Start 09/2013 
End 09/2016
 
Description Breaking the scarlet fever transmission chain to reduce invasive streptococcal infection.
Amount £188,536 (GBP)
Funding ID 2596 
Organisation Action Medical Research 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2017 
End 08/2020
 
Description Breast Cancer Campaign project grant
Amount £191,000 (GBP)
Funding ID 2014MayPR234 
Organisation Breast Cancer Campaign (BCC) 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2014 
End 10/2017
 
Description Breast Cancer Campaign small pilot grant
Amount £20,000 (GBP)
Funding ID 2013MaySP004 
Organisation Breast Cancer Campaign (BCC) 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2013 
End 08/2014
 
Description British Lung Foundation Napp travel fellowship
Amount £750 (GBP)
Organisation British Lung Foundation (BLF) 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description CRUK Programme Grant
Amount £3,000,000 (GBP)
Funding ID C37/A18784 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2015 
End 09/2020
 
Description Confidence in Concept
Amount £840,000 (GBP)
Funding ID MC_PC_16046 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2017 
End 02/2019
 
Description Confidence in Concept
Amount £944,000 (GBP)
Funding ID MC_PC_17162 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2018 
End 02/2020
 
Description Confidence in Concept
Amount £700,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2013 
End 09/2015
 
Description Confidence in Concept 3
Amount £800,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2015 
End 09/2016
 
Description Confidence in Concept 4
Amount £900,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2016 
End 02/2018
 
Description Dexcom Industry Funding
Amount £191,757 (GBP)
Organisation Dexcom 
Sector Private
Country United States
Start  
 
Description Doverdale Trust Fund
Amount £16,133 (GBP)
Organisation Royal Brompton & Harefield NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 05/2014 
End 12/2014
 
Description EPSRC i-sense IRC Fellowship
Amount £184,041 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start  
 
Description EPSRC i-sense IRC Fellowship
Amount £201,028 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start  
 
Description Egyptian Newton Fund
Amount £150,000 (GBP)
Organisation British Council 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2015 
 
Description Halley Stewart Fellowship
Amount £5,000 (GBP)
Organisation Sir Halley Stewart Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2013 
End 10/2015
 
Description Horizon 2020
Amount € 1,218,879 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start  
 
Description ICiC 1 - Quinlan - British Heart Foundation Translational Award Scheme "Development of a haemolysis triple filter for use in extracorporeal circuits"
Amount £317,000 (GBP)
Funding ID TG/18/7/34132 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2019 
End 06/2022
 
Description ICiC 1_Schneider_MAP4K4 Apollo
Amount £2,800,000 (GBP)
Organisation Apollo Therapeutics 
Sector Private
Country United Kingdom
Start 04/2019 
End 04/2020
 
Description Late Stage Seeding Drug Discovery Award
Amount £4,499,155 (GBP)
Funding ID 205256/Z/16/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2017 
End 11/2019
 
Description MRC Project Grant
Amount £519,555 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description Medicor funding
Amount £200,000 (GBP)
Organisation Medicor Foundation 
Sector Charity/Non Profit
Country Liechtenstein
Start 12/2013 
 
Description Merieux Foundation
Amount € 100,000 (EUR)
Organisation Merieux Foundation 
Sector Charity/Non Profit
Country France
Start 07/2014 
End 08/2016
 
Description Molecular Dissection of England's Scarlet Fever Upsurge 2015-2016 and Impact on Invasive Infections
Amount £415,642 (GBP)
Funding ID MR/P022669/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 06/2017 
End 06/2020
 
Description NIHR Imperial BRC - BioAID
Amount £421,836 (GBP)
Organisation National Institute for Health Research 
Department NIHR Imperial Biomedical Research Centre
Sector Public
Country United Kingdom
Start 03/2014 
End 03/2017
 
Description NIHR Invention for Innovation (I4I)
Amount £718,235 (GBP)
Funding ID II-LA-0313-20004 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 03/2014 
End 04/2017
 
Description NIHR Respiratory Biomedical Research Unit funding for PhD fellows
Amount £180,000 (GBP)
Organisation Royal Brompton & Harefield NHS Foundation Trust 
Department NIHR Biomedical Research Unit
Sector Public
Country United Kingdom
Start 08/2013 
End 08/2016
 
Description Proof of Concept funding - Imperial Innovations
Amount £24,954 (GBP)
Organisation Imperial Innovations 
Sector Private
Country United Kingdom
Start 12/2014 
End 04/2015
 
Description Royal Brompton & Harefield NHS Foundation Trust Seed Funding
Amount £10,000 (GBP)
Organisation Royal Brompton & Harefield NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 01/2016 
End 10/2016
 
Description Royal Society of Chemistry Travel Grant
Amount £3,065 (GBP)
Organisation Royal Society of Chemistry 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Studentship EPSRC CDT in Neurotechnology for Life and Health
Amount £96,000 (GBP)
Organisation Imperial College London 
Department EPSRC Centres for Doctoral Training
Sector Academic/University
Country United Kingdom
Start 08/2014 
End 09/2018
 
Description Targeting bacterial virulence as a novel antibiotic and vaccine approach
Amount £106,212 (GBP)
Funding ID BB/R505766/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2017 
End 10/2021
 
Description Understanding and exploiting Group A streptococcal anti-chemotactic proteases in vaccines for infection
Amount £1,655,729 (GBP)
Funding ID 215539/Z/19/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2018 
End 06/2026
 
Description Wellcome Portfolio Grant for Alpha 1 antitypsin deficiency and haemophilia
Amount £6,400,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2017 
 
Description Wellcome Trust Extension Translation Award - A Bio-inspired Artificial Pancreas for Control of Type 1 Diabetes in the Home
Amount £193,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
 
Description Wellcome Trust Imperial ISSF Sabbatical Award
Amount £3,500 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2014 
End 01/2015
 
Description Wellcome Trust Seeding Drug Discovery
Amount £2,700,000 (GBP)
Funding ID 10638/Z/14/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2015 
End 05/2017
 
Description icIC 1 - Herrero- Dexcom
Amount £450,000 (GBP)
Organisation Dexcom 
Sector Private
Country United States
Start 11/2018 
End 11/2019
 
Title Edwards - P47173 
Description Developed a novel cell based screening assay involving the activation of two virus-inducible transcription factors; NF-?B, required for over 100 pro-inflammatory cytokines and IRF3; a transcription factor central to IFN gene expression. 
Type Of Material Model of mechanisms or symptoms - in vitro 
Provided To Others? No  
Impact N/A 
 
Title Giamas - LMTK3 inhibitors 
Description Potential new inhibitor against a kinase implicated in cancer development. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact None stated at present 
 
Title Griesenbach - P47167-plasmids suitable for the production of F/HN pseudotyped lentiviral vectors carrying FVIII 
Description As part of this project Professor Griesenbach's team generated plasmids suitable for the production of F/HN pseudotyped lentiviral vectors carrying FVIII. Lentiviral vectors have been constructed and assessed for efficacy in relevant models 
Type Of Material Biological samples 
Provided To Others? No  
Impact Presented work related to the novel vector platform at the American Society for Gene Therapy Symposium 2014 
 
Title Srsikandan - ICiC1 - E-VIG 
Description E-IVIG demonstrated to be a highly purified protective derivative of regular IVIG in vitro and in treatment of invasive group A streptococcal infection. Reagent described in Scientific Reports (Reglinski et al, 2015) 
Type Of Material Technology assay or reagent 
Year Produced 2015 
Provided To Others? Yes  
Impact Other academic groups have used IVIG as a positive control for development of surrogate of immunity assays for GAS . 
 
Title ICiC 1 - Herrero - ABC4D Phase 3 Dataset 
Description The database includes data from 25 adults with type 1 diabetes on multiple daily injection, insulin pump therapy and wearing a continuous glucose monitor, and using the ABC4D app. Each participant was using the system for a duration of 6 months. The dataset includes: continuous glucose data and manual data logs (carbohydrates, insulin, exercise, glucose trends, capillary glucose). 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
Impact The database is currently being used to develop machine learning algorithms for glucose prediction and classification. 
 
Description Edward, M - P47173 - Domainex 
Organisation Domainex
Country United Kingdom 
Sector Private 
PI Contribution Imperial provided in-house small molecule library
Collaborator Contribution Domainex screened Imperial in-house small molecule library
Impact Azithromycin augments RV-induced type I IFN and type III IFNs via interaction with MAVS. Michael R Edwards Oral Presentation, XVI International Symposium on Respiratory Viral Infections Seoul, Korea 2014. http://www.themacraefoundation.org/wp-content/uploads/2013/08/Final-Program-2.pdf Novel inhibitors of TGF-? activating kinase (TAK1) uncouple beneficial anti-viral innate immunity from harmful virus-induced pro-inflammatory responses in models of rhinovirus infection. Michael R. Edwards, Katie Chapman, Jennifer J. Haas, Louise Slater, Albert Jaxa-Chamiec, Caroline Low, Hayley Cordingley, Roberto Solari, Sebastian L. Johnston Catherine Tralau-Stewart. Poster Presentation, American Thoracic Society, San Diego, USA 2014. The collaboration is multi-disciplinary; cell biology, immunology, drug discovery and chemistry are the various disciplines involved.
Start Year 2013
 
Description Edwards - P47173 - UCSD 
Organisation University of California, San Diego (UCSD)
Country United States 
Sector Academic/University 
PI Contribution Edwards team has identified demethylasterrquinone as a novel inhibitor of TAK1 and NF-?B
Collaborator Contribution Mike Pirrung & Nicholas Webster at Uni of California, San Diego - provided library of novel asterrquinones based around the structure of demethylasterrquinone (under MTA)
Impact The collaboration is multi-disciplinary; cell biology, immunology, drug discovery and chemistry are the various disciplines involved.
Start Year 2013
 
Description Edwards, M - P47173 - Pfizer 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution Edwards team identified several new that increased virus-induced IFN induction by 200-250% and decreased pro-inflammatory cytokine induction by 60-80% from the small library of macrolides provided for screening by Pfizer.
Collaborator Contribution Pfizer USA - small library of macrolides provided for screening.
Impact Have identified new macrolides with Pfizer, still awaiting outcomes. The collaboration is multi-disciplinary; cell biology, immunology, drug discovery and chemistry are the various disciplines involved.
Start Year 2010
 
Description Giamas - P47199 - Biofocus 
Organisation Biofocus
Country United States 
Sector Private 
PI Contribution Giamas' team provided Biofocus with the protein to do the assay/screening.
Collaborator Contribution Biofocus performed the screening and analysed the data.
Impact None stated
Start Year 2013
 
Description Giamas - P47199 - OPPF 
Organisation Research Complex at Harwell
Department Oxford Protein Production Facility-UK (OPPF-UK)
Country United Kingdom 
Sector Academic/University 
PI Contribution As part of this work and in collaboration with OPPF (Oxford Protein Production Facility) Dr Giamas' team have generated additional LMTK3 constructs encompassing the kinase domain that were expressed in various systems (E. Coli, insect cells, etc).
Collaborator Contribution As part of this work and in collaboration with OPPF (Oxford Protein Production Facility) Dr Giamas' team have generated additional LMTK3 constructs encompassing the kinase domain that were expressed in various systems (E. Coli, insect cells, etc). OPPF produced the proteins for use in these experiments.
Impact Dr Giamas' team managed to generate more pure and conformationally accurate LMTK3 protein that has been tested positive for kinase activity in in vitro kinase assays.
Start Year 2013
 
Description Giamas - P47199 - ProfNC 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Generated more pure and conformationally accurate LMTK3 protein that has been tested positive for kinase activity in in vitro kinase assays
Collaborator Contribution This LMTK3 protein is currently being used by our collaborator Professor Naomi Chayen (Imperial College) in crystallography assays
Impact Yes this is a multi-disciplinary collaboration: Basic research (molecular, cell biology) along with structural biology.
Start Year 2013
 
Description Griesenbach - ICiC1 - Prof Amit Nathwani 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Expertise in pulmonary gene transfer and the generation of suitable vectors.
Collaborator Contribution Expertise in the relevant disease area and access to patients should a clinical trial be initiated.
Impact N/A
Start Year 2016
 
Description Griesenbach - P47167 - ProfAN 
Organisation University College London
Department UCL Cancer Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration with Prof A Nathwani to ensure smooth progression of Professor Grisenbach's gene transfer strategies into clinic, once efficacy in pre-clinical models has been determined
Collaborator Contribution Collaboration with Prof A Nathwani to ensure smooth progression of Professor Grisenbach's gene transfer strategies into clinic, once efficacy in pre-clinical models has been determined
Impact n/a
Start Year 2013
 
Description Griesenbach - P47167 - UKCFGTC 
Organisation Baylor College of Medicine
Department Centre for Cell and Gene Therapy
Country United States 
Sector Academic/University 
PI Contribution All work performed within the UK CF Gene Therapy Consortium is performed in a collaborative fashion across the three sites. The relative contributions of each site are project specific. For the project in question efficacy testing of viral vectors was performed by the Imperial team.
Collaborator Contribution All work performed within the UK CF Gene Therapy Consortium is performed in a collaborative fashion across the three sites. The relative contributions of each site are project specific. For the project in question viral vectors were produced by the Oxford arm of the consortium.
Impact The Consortium is now the world's largest gene therapy group focused on a single disease, with a combined staff of over 50. Professor Griesenback's team of clinical trial programme is well underway. Medicor awarded £200,000 to the whole of the GTC for the continuation of Consortium CF Gene Therapy work. The award was made on 20/12/13.
Start Year 2006
 
Description Herrero - ICiC1 - Dexcom, Inc, San Diego, USA 
Organisation Dexcom
Country United States 
Sector Private 
PI Contribution Development of the ABC4D app iOS and backend software (Matlab and webserver) to perform the clinical trial.
Collaborator Contribution Financial support and providing some feedback regarding the usability of the app.
Impact N/A
Start Year 2015
 
Description Herrero-Viñas - P47176 - C 
Organisation Cellnovo
Country United Kingdom 
Sector Private 
PI Contribution Cellnovo (pump manufacturer) is interested in incorporating Dr Herrero-Vinas' software solution (ABC4D) in their products. Dr Herrero-Vinas' team are currently working on such integration.
Collaborator Contribution Cellnovo (pump manufacturer) is interested in incorporating Dr Herrero-Vinas' software solution (ABC4D) in their products. Dr Herrero-Vinas' team are currently working on such integration.
Impact Dr Herrero-Vinas' team are looking at incorporating ABC4D application into the Cellnovo handheld unit, which already communicates to their insulin pump.
Start Year 2014
 
Description Herrero-Vinas - P47176 - D 
Organisation Dexcom
Country United States 
Sector Private 
PI Contribution Dexcom has provided Dr Herrero-Vinas' team with two investigational devices. The team's main aim is to promote their product among the scientific community since bigger stakeholders such as Medtronic currently dominate the market. Therefore, by acknowledging them in the publications and conferences, the team are benefiting them by publicizing their product.
Collaborator Contribution Dexcom has provided Dr Herrero-Vinas' team with two investigational devices. The team's main aim is to promote their product among the scientific community since bigger stakeholders such as Medtronic currently dominate the market. Therefore, by acknowledging them in the publications and conferences, the team are benefiting them by publicizing their product.
Impact N/A
Start Year 2014
 
Description ICiC 1 - Schneider - Novel inhibitors of Nemo-like kinase (NLK) to suppress cardiac muscle cell death 
Organisation Domainex
Country United Kingdom 
Sector Private 
PI Contribution Target selection, forward plan for in-cell function and progression to small-mammal models
Collaborator Contribution Fragment-based screen and medicinal chemistry
Impact No outputs yet
Start Year 2017
 
Description ICiC 1 - Sriskandan - GSK Golden Triangle Grand Challenge 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Proposed the collaboration and ideas; provided reagents and expertise; collaborated and monitored progress; Provided PhD student to undertake some scientific work
Collaborator Contribution Commercial partner undertook large amount of scientific work
Impact Work that will contribute to a PhD thesis. Work that will contribute to joint papers in due course.
Start Year 2017
 
Description ICiC Quantum Dot Biosensor System 
Organisation Imperial College London
Department Department of Bioengineering
Country United Kingdom 
Sector Academic/University 
PI Contribution For this ICiC project the bioengineers are developing nanoparticle-based assay for the detection of miRNAs, which will be derived from clinical samples provided by the NHLI collaborators. The Confidence in Concept grant made this collaboration possible.
Collaborator Contribution The investigators at NHLI are providing clinical samples for the assay development.
Impact None so far, project only commenced September 2013. Outputs expected by the next reporting period (October 2014). The work is multi-disciplinary involving bionanotechnology (specifically harnessing the unique properties of nanomaterials in biosensors that should enable highly sensitive and rapid detection of clinically relevant biomarkers) and the collaborators are clinicians working in The Royal Brompton Hospital, researching in cardiac related areas.
Start Year 2013
 
Description ICiC Quantum Dot Biosensor System 
Organisation Imperial College London
Department National Heart & Lung Institute (NHLI)
Country United Kingdom 
Sector Academic/University 
PI Contribution For this ICiC project the bioengineers are developing nanoparticle-based assay for the detection of miRNAs, which will be derived from clinical samples provided by the NHLI collaborators. The Confidence in Concept grant made this collaboration possible.
Collaborator Contribution The investigators at NHLI are providing clinical samples for the assay development.
Impact None so far, project only commenced September 2013. Outputs expected by the next reporting period (October 2014). The work is multi-disciplinary involving bionanotechnology (specifically harnessing the unique properties of nanomaterials in biosensors that should enable highly sensitive and rapid detection of clinically relevant biomarkers) and the collaborators are clinicians working in The Royal Brompton Hospital, researching in cardiac related areas.
Start Year 2013
 
Description Long - P46365 - Uni of Manchester 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution We made the compound that Professor Allen then tested in a stroke model, coupled with magnetic resonance imaging (MRI)
Collaborator Contribution Prof Allen tested the compound in his in vivo stroke model and then performed MRI
Impact This project has strengthening the link between Professor Allen and Professor Long's group, and further between Manchester University and Imperial College.
 
Description Oliver ICiC - University of Surrey 
Organisation University of Surrey
Country United Kingdom 
Sector Academic/University 
PI Contribution Develop and clinically assess a novel continuous glucose monitor (CGM) that overcomes challenges facing commercially available CGM technology by providing an accurate, painless minimally invasive device.
Collaborator Contribution To obtain a higher quality of gold coating for the device (essential for its intended function), Nick Oliver's team used the conformal sputtering machine at University of Surrey.
Impact Obtaining gold coated devices of higher quality
Start Year 2013
 
Description Quinlan - DrND 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution At Imperial we have produced a functioning a filter prototype.
Collaborator Contribution UCL will test this (filter prototype) in an in vivo model of haemolysis.
Impact Multidisciplinary; within Imperial involving Medicine and Chemistry and from UCL hepatology. Functioning prototype produced
Start Year 2013
 
Description Quinlan - ICiC1 - BPL 
Organisation Bio Products Laboratory Ltd
Country United Kingdom 
Sector Private 
PI Contribution BPL are the providers of Haptoglobin which is utilised as a component of the filter device. Gregory Quinlan's team actually have a CDA in place with BPL going back seven years (facilitated though UCL).
Collaborator Contribution Gregory Quinlan's team are about to send them a technical report including a description our expectations from BPL. This collaboration was initiated prior to the ICiC award but is important to Dr Quinlan's ICiC1 project.
Impact A device in the form a filter to remove haemoglobin and related products from blood for the incorporation in extracorporeal circuits.
Start Year 2007
 
Description Schneider - PS2145 - Domainex 
Organisation Domainex
Country United Kingdom 
Sector Private 
PI Contribution The Schneider laboratory has been responsible for the cell biology, functional genomics, and molecular physiology: namely, the development and implementation of cardioprotection assays in human pluripotent stem cell-derived cardiomyocytes, the RNA interference results validating MAP4K4 as a druggable target in the human context, and demonstrating the effectiveness of our best compound in this system.
Collaborator Contribution We have collaborated with Cambridge drug discovery firm Domainex since mid-2013 for molecular modelling, medicinal chemistry, and strategic advice. In addition, the cell-free assays have been performed by Dr Chapman there.
Impact This is a multi-disciplinary collaboration, including cell biology, functional genomics, and molecular physiology.
Start Year 2013
 
Description Snelgrove - ICiC1 - DAG 
Organisation University of Alabama at Birmingham
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution Provision and testing of our novel Leukotriene A4 hydrolase (LTA4H) modulators in murine models and clinical samples
Collaborator Contribution Provision of specific mouse strains and expertise in murine models. Provision of clinical samples. Some downstream analysis.
Impact No impact so far, collaboration and work still on-going.
Start Year 2015
 
Description Snelgrove - ICiC1 - PIP & DMB 
Organisation University of Oxford
Department Nuffield Department of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Measurement of Leukotriene B4 (LTB4) and PGP in clinical samples via mass spectrometry.
Collaborator Contribution Provision of clinical samples.
Impact Studies formed part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme.
Start Year 2015
 
Description Snelgrove - ICiC1+2 - DrSH 
Organisation Imperial College London
Department Department of Life Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Generation / provision of novel Leukotriene A4 hydrolase (LTA4H) modulators and recombinant LTA4H enzyme. Knowledge of LTA4H active site and Structure-Activity Relationship (SAR) studies.
Collaborator Contribution Expertise in X-ray crystallography - conducted experiments and analysis.
Impact Successful generation of X-ray crystallography structures of lead compounds bound within active site of LTA4H. These will form part of a manuscript currently in preparation. They were also part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme.
Start Year 2014
 
Description Snelgrove - ICiC1+2 - ProfCL 
Organisation Imperial College London
Department National Heart & Lung Institute (NHLI)
Country United Kingdom 
Sector Academic/University 
PI Contribution We have utilised Professor Lloyd's models of allergic airways disease to test our LTA4H knock-out mice and LTA4H modulators. We conducted all experiments and analysis with some technical help from Professor Lloyd's group,
Collaborator Contribution Professor Lloyd is a world leader in murine models of allergic airways disease. She has provided expertise and knowledge of the models and her group have provided technical assistance.
Impact Successful application for an Asthma UK Innovations award. Studies also formed part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme. These studies are the subject of a manuscript currently being finalized.
Start Year 2013
 
Description Snelgrove - Peakdale Molecular 
Organisation Peakdale Molecular
Country United Kingdom 
Sector Private 
PI Contribution We have formed a collaboration with Peakdale Molecular for the outsourcing of drug synthesis. Whilst there is an on-going narrative between ourselves and Peakdale about the drug synthesis pathways, they are largely providing a service.
Collaborator Contribution In essence, we inform them of the compounds that we would like synthesized and then subsequently pay them to make them
Impact The collaboration has been successful in the synthesis of novel compounds that show distinction between the dual activities of LTA4H, as well as the production of current pharmaceutical LTA4H inhibitors (to which we will be comparing our compounds ).
Start Year 2013
 
Description Stronach - P47197 - Cyprotex 
Organisation Cyprotex
Country United Kingdom 
Sector Private 
PI Contribution The interaction with Cyprotex was purely fee for service for kinome screen and ADMET assays respectively.
Collaborator Contribution The interaction with Cyprotex was purely fee for service for kinome screen and ADMET assays respectively.
Impact Nothing stated
Start Year 2013
 
Description Stronach - P47197 - Dundee MRC 
Organisation Dundee Model Railway Club
Country United Kingdom 
Sector Private 
PI Contribution The interaction with Dundee MRC unit was purely fee for service for kinome screen and ADMET assays respectively
Collaborator Contribution The interaction with Dundee MRC unit was purely fee for service for kinome screen and ADMET assays respectively
Impact We have commissioned the Dundee MRC Unit to run kinase profiling on 4 compounds. This is underway and we await data return. This will give us key information on how clear or otherwise the compounds are.
Start Year 2013
 
Description Stronach - P47197 - Edinburgh Bioquarter 
Organisation Edinburgh bioQuarter
Country United Kingdom 
Sector Private 
PI Contribution None stated
Collaborator Contribution The Edinburgh BioQuarter collaboration began with this project in 2013. BioQ provided important validation of compound phenotype effects in an independent lab. They also carried out detailed time course proteomics and identified pharmacodynamic biomarkers of compound activity. The data produced collectively is being compiled into a patent application for the key structures produced within this project. This is in progress.
Impact n/a as this is still on-going
Start Year 2013
 
Description Taylor-Robinson - ICiC 1 - Prolifica (IMF) 
Organisation Merieux Institute
Country France 
Sector Private 
PI Contribution The Taylor-Robinson group have ongoing liver cancer biomarker work in Africa to develop a low cost urinary diagnostic which is being funded by Institut Merieux. The monies have facilitated collection of samples by the team in Nigeria, Gambia and Senegal and the analysis of samples at Imperial College London
Collaborator Contribution Financial funding - Ongoing Institut Merieux funding until August 2016 (2 years) for 100,000 euros per year to further fund the liver cancer biomarker work in Africa
Impact Not yet - ongoing
Start Year 2014
 
Description West African Liver Cancer Network 
Organisation Academy of Sciences of the Republic of Tajikistan
Department Institute of Gastroenterology
Country Tajikistan 
Sector Academic/University 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation European Commission
Department Seventh Framework Programme (FP7)
Country European Union (EU) 
Sector Public 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation Imperial College London
Department Faculty of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation International Agency for Research on Cancer (IARC)
Department Virology Department
Country France 
Sector Academic/University 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation Le Dantec Hospital
Country Senegal 
Sector Hospitals 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation Medical Research Council (MRC)
Department MRC Unit, The Gambia
Country Gambia 
Sector Public 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation Ministry of Health
Country Rwanda 
Sector Public 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation Muhimbili University of Health and Allied Sciences
Department Department of Haematology and Blood Transfusion
Country Tanzania, United Republic of 
Sector Academic/University 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation Royal Victoria Teaching Hospital
Department Department of Medicine
Country Gambia 
Sector Hospitals 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation Thies Medical School
Department Department of Medicine
Country Senegal 
Sector Academic/University 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation University of Jos
Department Department of Gastroenterology
Country Nigeria 
Sector Academic/University 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation West African College of Physicians
Country Nigeria 
Sector Charity/Non Profit 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description West African Liver Cancer Network 
Organisation Xeptagen Ltd, Venice, Italy
Country Italy 
Sector Private 
PI Contribution Development of urinary biomarkers for detection of liver cancer for resource poor countries using NMR spectroscopy and mass spectroscopy.
Collaborator Contribution Provision of clinical material and clinical expertise in West Africa and Central Asia
Impact Invitations to multiple international conferences to present results (see awards & recognition) and invitation for potential further funding from industry (GE Healthcare). One patent granted and one patent published.
Start Year 2013
 
Description Wigneshweraraj - P47143 - D 
Organisation Domainex
Country United Kingdom 
Sector Private 
PI Contribution Prof. Wigneshweraraj's team screened the efficiency of libraries of small molecules identified by Domainex scientists to inhibit the enzymatic activity of the bacterial RNA polymerase and growth of Escherichia coli.
Collaborator Contribution Prof. Wigneshweraraj's team screened the efficiency of libraries of small molecules identified by Domainex scientists to inhibit the enzymatic activity of the bacterial RNA polymerase and growth of Escherichia coli.
Impact We are currently preparing a preliminary application for a Wellcome Trust SDDI scheme. Awaiting decision from a BBSRC grant application.
Start Year 2013
 
Title Advance Bolus Calculator for Diabetes Management (ABC4D) 
Description The Advanced Bolus Calculator for Diabetes (ABC4D) is a decision support system based on case-based reasoning (CBR). CBR is an artificial intelligence problem solving framework that solves a newly encountered problem (e.g. meal insulin dosing), based on the information obtained from previously solved problems (cases). ABC4D is implemented in a smartphone application and utilises continuous glucose monitoring data to provide personalised and adaptive insulin bolus advice. Safety and clinical feasibility of the ABC4D app have been evaluated on 10 type 1 subject over a period of 6 weeks. 
IP Reference  
Protection Protection not required
Year Protection Granted 2015
Licensed No
Impact N/A
 
Title DIAGNOSTIC METHOD 
Description Methods and kits for analysing a sample from a test subject. The methods involve determining the level of at least one compound selected from the group consisting of N- acetylglutamate, methionine, acetylcarnitine, indole-3 -acetate, 2-oxoglutarate, anserine, aspartate and butyrate in the sample from the test subject; and comparing the level of the at least one compound determined to at least one control level, wherein the levels of the at least one compound are indicative of whether the subject has hepatic cancer. 
IP Reference WO2014174275 
Protection Patent granted
Year Protection Granted 2014
Licensed No
Impact None stated
 
Title Methods for categorising cancer such as breast cancer 
Description LMTK3 as a prognostic marker for breast cancer treatment and to select appropriate therapy 
IP Reference US20110123386 
Protection Patent application published
Year Protection Granted 2010
Licensed No
Impact Breast Cancer Campaign small Pilot grant nominated to Dr Georgios Giamas (Ref No: 2013MaySP004). 'Assay development and hit finding against LMTK3'. 1 year grant from 19th August 2013. Total value = £20,000. Action Against Cancer grant. PI: Prof Justin Stebbing. 'Assay Development and Compounds Screening for LMTK3'. 1st July 2012 to 30th June 2015. Total value = £78,000 9th International Conference of Anticancer Research, 6-10 October 2014, Sithonia, Greece (Oral presentation) 'Positioning LMTK3 on the map of oncogenic signalling cascades and elucidating its role in invasion and metastasis in Breast Cancer'
 
Title Coombes - ICEC0942 
Description We have developed selective small molecule inhibitors of cyclin-dependent kinases, CDK7 and CDK9, which are required for regulation of transcription in metazoans. Cancer features many oncogenes that are transcriptional regulators and targeting transcription would provide a powerful anti-tumour strategy. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2014
Development Status Actively seeking support
Impact N/A 
 
Title Giamas - LMTK3 inhibitor 
Description This work is currently funded by Action Against Cancer. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2014
Development Status Actively seeking support
Impact N/A 
 
Title Herrero-Viñas - P47176 - ABC4D 
Description This study aims to assess the safety and efficacy of a novel advanced bolus calculator in subjects with Type 1 diabetes. Insulin bolus calculators have been developed to aid insulin dose adjustment and existing standard insulin bolus calculator consist of a simple algorithm that requires five subject-specific parameters as input to generate a recommended bolus insulin dose: current blood glucose (mmol/L); target blood glucose (mmol/L); insulin-to-carbohydrate ratio (grams of carbohydrate per 1 unit of insulin); total grams of carbohydrate in meals; insulin sensitivity factor (reduction in glucose per 1 unit of insulin). The Diabetes Technology team at Imperial College have developed a novel advanced bolus calculator. The complete integrated system consists of a commercially available smartphone that holds the novel advanced algorithm. The system requires regular updates of cases derived from retrospective blinded continuous glucose monitoring data and for this a commercially available glucose sensor will be used. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (blood glucose following a meal). The novel decision support algorithm is based on case-based reasoning (CBR). CBR is an artificial intelligence technique that tries to solve newly encountered problems by applying the solutions learned from solved problems encountered in the past. The end-product is therefore a subject specific insulin bolus calculator that continues to improve with time. The project utilises commercially available glucose sensors and smartphones (iPhone), integrated with a novel algorithm for insulin bolus calculation. The aim of the ABC4D is to minimise high and low glucose excursions which are associated with the complications of diabetes including blindness, kidney failure, nerve damage and cardiovascular disease. The clinical study has been designed to incrementally assess the device's ability to manage meal time insulin requirements at breakfast and lunch in a controlled supervised clinical environment over 8 hours (phase 1), followed by its use in the home environment over a 6 week period (phase 2) and finally over a 6 month period (phase 3). The most recent principle source of funding has been 'Imperial Confidence in Concept Scheme & Imperial NIHR Biomedical Research Centre /Imperial Innovations Therapeutic primer fund'. The clinical trial (phase 2) is currently active with the available funding. We are currently actively seeking for more funding to carry out the next phase of the clinical trial (phase 3). 
Type Management of Diseases and Conditions
Current Stage Of Development Refinement. Clinical
Year Development Stage Completed 2014
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Very positive feedback on usability of the ABC4D system was obtained from a focus group carried out with six volunteers with type 1 diabetes. 
URL http://clinicaltrials.gov/show/NCT02053051
 
Title Oliver ICiC - Microprobe array continuous glucose monitor 
Description The device consists of a patch containing several microscopic projections. When applied to skin surface, these projections painlessly penetrate the outermost skin layer to sense glucose level within the tissues in a continuous manner. It aims at overcoming drawbacks of existing technology particularly by providing painless and more accurate continuous glucose readings. We are currently assessing the device's safety and performance in clinical studies and we are funded by a grant for NIHR I4I scheme. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Refinement. Clinical
Year Development Stage Completed 2013
Development Status Under active development/distribution
Impact Potentially, the device could allow a more accurate and significantly cheaper technology for continuous glucose monitoring (CGM), which can subsequently result in wider use of this technology in people with diabetes. CGM was shown to improve control of diabetes with subsequent reduction in complications. 
URL http://clinicaltrials.gov/ct2/show/NCT01908530?term=microprobe&rank=1
 
Title Simonds ICiC - Evaluating intelligent oxygen therapy 
Description NIHR Respiratory BRU funding for PhD fellow 
Type Therapeutic Intervention - Medical Devices
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2014
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Trial ongoing 
 
Description Edwards - P47173 - American Thoracic Society 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach International
Primary Audience Patients, carers and/or patient groups
Results and Impact Presented a poster at at poster discussion session (ATS) the audience were approx several hundred, the abstract would reach several thousand.

Novel inhibitors of TGF-beta activating kinase (TAK1) uncouple beneficial anti-viral innate immunity from harmful virus-induced pro-inflammatory responses in models of rhinovirus infection. Michael R. Edwards, Katie Chapman, Jennifer J. Haas, Louise Slater, Albert Jaxa-Chamiec, Caroline Low, Hayley Cordingley, Roberto Solari, Sebastian L. Johnston Catherine Tralau-Stewart. Poster Presentation, American Thoracic Society, San Diego, USA 2014.

N/A
Year(s) Of Engagement Activity 2014
URL http://www.thoracic.org/
 
Description Edwards - XVI International Symposium on Respiratory Viral Infections Seoul, Korea 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach International
Primary Audience Other audiences
Results and Impact Presented a seminar at a virology conference (RVI) the audience were approx several hundred, the abstract would reach several thousand.

N/A
Year(s) Of Engagement Activity 2014
URL http://www.themacraefoundation.org/wp-content/uploads/2013/08/Final-Program-2.pdf
 
Description Edwards, M - American Thoracic Society, San Francisco 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Azithromycin Augments RV-Induced Type I & III IFN Production Via Interaction with MAVS Michael R. Edwards, James D. Porter, Musa Khaitov, Sergei Moshkovski , Lyn Jones, Lee Roberts, Kalesh K.N. Anandamma, Iain Kilty, Ed Tate, Sebastian L. Johnston. Oral Presentation, American Thoracic Society, San Francisco, USA 2016.

A talk of 15 minutes, and discussion for 5-7 mins including questions from the audience. Outcome was to disseminate information regarding science and asthma treatments. Outcome or impact is unknown.
Year(s) Of Engagement Activity 2016
URL http://www.atsjournals.org/doi/abs/10.1164/ajrccmconference.2016.193.1_MeetingAbstracts.A6421
 
Description Gavins - Experimental Biology 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Research presentation to colleagues biology and imaging fields. Good discussion on specific and wider aspects of f-element chemistry

N/A
Year(s) Of Engagement Activity 2014
URL http://experimentalbiology.org/2014/Home.aspx
 
Description Giamas - P47199 - 9th International Conference of Anticancer Research 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Approximately 50 scientists attended the talk, followed by questions and discussion.

Potential future collaborations with other groups were discussed.
Year(s) Of Engagement Activity 2014
URL http://www.iiar-anticancer.org/conference/
 
Description Griesenbach - ICiC1 - Rare Disease Day 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Raising awareness for genetic diseases.
Year(s) Of Engagement Activity 2016
 
Description Griesenbach - Imperial Festival 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Approximately 12,000 people attended Imperial Festival over 3 days.

Sharing information and improving public understanding of research
Year(s) Of Engagement Activity 2012,2014
URL http://www3.imperial.ac.uk/festival
 
Description Griesenbach - P47167 - Heart and Lung Repair Shop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact The audience were asked to vote on The Heart and Lung Repair Future Challenges. The winning challenge, receiving 699 votes, was 'Repair Your Own Organs' which was a challenge to develop drugs to stimulate the body's own stem cells to heal itself. The other challenges were 'Build a Heart' receiving 184 votes, 'Make Cigarettes Healthy' receiving 278 votes and 'Better Treatment for Lung Cancer' receiving 408 votes; special events were held including debates about the future of heart and lung repair, facilitated by Y Touring Theatre Company and a debate workshop with students from Hammersmith Academy.

2750 people visited The Heart and Lung Repair Shop during the two weeks it was open.
Year(s) Of Engagement Activity 2014
URL http://www1.imperial.ac.uk/nhli/public_engagement/the_curious_act/heart_and_lung_repair_shops/
 
Description Griesenbach - P47167 - In2SUK 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? Yes
Geographic Reach Local
Primary Audience Schools
Results and Impact In2science scheme works to leverage the commitment, passion and experience of scientists to ensure the brightest pupils have the opportunity to experience research science first hand, regardless of their wealth. Students work alongside practising scientists for a 2 week placement during the summer, giving students an insight into scientific research.

Placements will be highly valued by future employers and admissions tutors at centres of higher education and will enable scientists to inspire the next generation. Several students requested to visit the laboratory to gain relevant experience before applying to university
Year(s) Of Engagement Activity 2014
URL http://in2scienceuk.org/scientist.html
 
Description Griesenbach - P47167 - Rare Disease Day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Since Rare Disease Day was first launched by EURORDIS and its Council of National Alliances in 2008, more than 1000 events have taken place throughout the world reaching hundreds of thousands of people and resulting in a great deal of media coverage.

Even though the campaign started as a European event, it has progressively become a world event, with a record-breaking 84 countries participating in 2014. IRRD hope many more will join in 2015. IRRD's objective is for the WHO to recognise the last day of February as the official Rare Disease Day and to raise increasing awareness for Rare Diseases worldwide.
Year(s) Of Engagement Activity 2008,2010,2012,2013,2014
URL http://www.rarediseaseday.org/article/what-is-rare-disease-day
 
Description Griesenbach - P47167 - STEML 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? Yes
Geographic Reach Local
Primary Audience Schools
Results and Impact The event aims to provide an insight on current popular research areas in different subject fields, and also gives students a chance to explore university life from a different prospective.

Several students requested to visit the laboratory to gain relevant experience before applying to university
Year(s) Of Engagement Activity 2014
URL http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/administration/outreach/eventssummary/...
 
Description Herrero - ICiC 1 - IBC 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation of the ABC4D system at the symposium organised by Astra-Zeneca entitled "Advances in Diabetes Technologies, Management and Prevention - An insight into Imperial College London's Innovative Research"
Year(s) Of Engagement Activity 2017
 
Description Herrero - ICiC 1 - IBC 2 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation of the ABC4D system at the symposium organised by Centre for Continuing Professional Development, Imperial College
Year(s) Of Engagement Activity 2017
 
Description Herrero - ICiC1 - Astra-Zeneka sponsored event in Madrid 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact More than 100 endocrinologists and around 15 from around Spain from Astra-Zeneka attended the talk (1 hour) about the ABC4D system which sparked questions and discussion afterwards.
Year(s) Of Engagement Activity 2017
 
Description ICiC 1 - Herrero - Advanced Technologies & Treatments for Diabetes (ATTD) conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 500 people attended the talk, which sparked questions and discussion afterwards
Year(s) Of Engagement Activity 2019
URL https://attd.kenes.com/2019#.XI_U-pP7Si4
 
Description ICiC 1 - Herrero - Scientific Sessions of the American Diabetes Association (ADA) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 1000 people attended the talk, which sparked questions and discussion afterwards
Year(s) Of Engagement Activity 2018
URL https://professional.diabetes.org/meeting/scientific-sessions/78th-scientific-sessions
 
Description ICiC 1 - Herrero - World Precision Medicine, AI in healthcare conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 50 people attended the talk, which sparked questions and discussion afterwards
Year(s) Of Engagement Activity 2018
URL http://allseq.com/conferences/world-precision-medicine-2018/
 
Description ICiC 1 - Sriskandan - 2. Invited lecture and participation in a WHO Consultation on Group A Streptococcal Vaccines May 16-17, 2018, held at the Wellcome Trust. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Third sector organisations
Results and Impact Roughly 50 attendees from around the world attended seminars and a workshop held at the Wellcome Trust organised by WHO about prospects for a global effort to develop a vaccine for group A streptococcus, and to develop a roadmap towards this goal, with funders, policymakers, and academics. This had led on to an application from IVI for a GAS Vaccine Consortium to Wellcome, and a federal award of A$35m from the Australian government to academic partners in Australia to further support development of a GAS vaccine.
Year(s) Of Engagement Activity 2018
 
Description ICiC 1 - Sriskandan - Imperial Vaccines Network symposium about commercial barriers to developing the most effective bacterial vaccines April 2017 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Third sector organisations
Results and Impact seminars given here were to other academics and stakeholders in the field including commercial vaccine developer. This led on to an active collaboration with the vaccine developer and a joint BBSRC iCASE (NPIF) studentship
Year(s) Of Engagement Activity 2018
 
Description ICiC 1 - Sriskandan - Invited seminar at the Institute of Global Health Innovation April 19th 2018 about " Why do we not have a vaccine for group A streptococcus?" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Third sector organisations
Results and Impact Seminars given here were to other academics and stakeholders in the field including commercial vaccine developer. This led on to an active collaboration with the vaccine developer and a joint BBSRC iCASE (NPIF) studentship
Year(s) Of Engagement Activity 2018
 
Description JDRF Discovery Evening 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Members of the ICiC project on Advanced Bolus Calculator for Diabetes presented their work at this event. This was an opportunity for adults living with type 1 diabetes to meet others with the condition and learn about the latest Juvenile Diabetes Research Foundation research. The event also included inspirational talks from adults living and working with Type 1 diabetes

Event occurred on 13th November 2013, no impact so far
Year(s) Of Engagement Activity 2013
URL http://www.jdrf.org.uk/research/research-events/type-1-discovery-evening
 
Description Long - P46365 - Dalton Discussion meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach International
Primary Audience Other audiences
Results and Impact There were presentations of research work, followed by extended question and answer sessions, where research issues were aired and talked through. This will affect future research and help to guide others research. There were further discussions during the lunch and evening sessions and the papers will be collected within a special issue of Dalton Transactions in February 2015.

As above, a special issue of the main UK inorganic chemistry journal will be the results of the meeting.
Year(s) Of Engagement Activity 2014
URL http://www.rsc.org/ConferencesAndEvents/RSCConferences/DD15/
 
Description Long - P46365 - DrGS - EU COST (EUFEN3) action meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Research presentation to colleagues in the f-element field. Good discussion on specific and wider aspects of f-element chemistry

Good discussion on specific and wider aspects of f-element chemistry
Year(s) Of Engagement Activity 2014
URL http://www.nottingham.ac.uk/~pczstl/CM1006/EUFEN3.htm
 
Description Long/Gavins - P46365 - Pharmacology 2014, London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Poster presentation given at pharmacology 2014 conference London. We hope the presentation will reach a wide audience and initiate conversations and debate about the work and future directions.

n/a
Year(s) Of Engagement Activity 2014
URL http://www.bps.ac.uk/meetings/Pharmacology2014
 
Description Oliver ICiC - The microprobe sensor advisory group 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? Yes
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact The group is formed of 8 members and meets on regular interval to discuss update and plans for the following phase of the project.

It allowed the group to view the project from patients' perspective and to modify the protocol accordingly. As mentioned, the group participated in protocol and in developing participant information material. The PPI at an early stage of this project was positively viewed by reviewers of the NIHR i4i grant (awarded on June 2013).
Year(s) Of Engagement Activity 2012,2013,2014
 
Description Shamji - British Society of Allergy and Immunology meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact British Society of Allergy and Immunology (BSACI) meeting, Telford, UK

Research findings were presented at the BSACI meeting. The symposium was attended by 50-100 delegates. Questions and Answer session was followed after the presentation

N/A
Year(s) Of Engagement Activity 2014
URL http://www.bsaci.org/announcements/bsaci-annual-meeting-2014
 
Description Shamji ICiC -American Academy of Allergy, Asthma and Immunology annual meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting in San Diego, USA.
The AAAAI featured poster session was well attended and a 5-10 minute presentations was given on the research, which was then followed by question and answer session. The session was attended by 50-100 delegates.

N/A
Year(s) Of Engagement Activity 2013,2014
URL http://annualmeeting.aaaai.org/
 
Description Simonds ICiC - European Respiratory Society (ERS) Summer School 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 80 doctors attended but presentations were disseminated on ERS website

Small group discussions on 02 therapy
Year(s) Of Engagement Activity 2014
URL http://www.ersnet.org/
 
Description Stevens - ICiC1 - APS Pharm Sci 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The Academy of Pharmaceutical Sciences held their annual PharmSci Conference at the University of Hertfordshire de Havilland campus, from 8th -10th September 2014. PharmSci 2014 addressed 'Working together for patients'. The conference attracted nearly 600 participants from academia, industry and regulatory authorities over the 3 days.

The conference also provided many networking opportunities and an enjoyable social side with a lively debate on the Monday evening, 'The role of universities in open innovation research: academic entrepreneurship or industrial exploitation?' and on the Tuesday evening the APS annual "Black Tie" Dinner at Knebworth House with an inspirational talk from Elin Haf Davies
Year(s) Of Engagement Activity 2014
URL http://www.ukpharmsci.org/2014resourcepack/
 
Description Stevens - ICiC1 - Corday Morgan Lecture (Award) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The Corday-Morgan Prizes are awarded for the most meritorious contributions to chemistry. It runs annually, there are up to three prizes available, winners receive £5000, a medal and a certificate, to be presented at the Prize ceremony in November, the winners will undertake UK lecture tours and prize winners are chosen by the RSC Awards Working Group. Prof Molly Stevens was the winner of this prize in 2014
Year(s) Of Engagement Activity 2014
URL http://www.rsc.org/events/detail/17280/2014-corday-morgan-prize-winner-lecture
 
Description Stevens - ICiC1 - Dara O'Brien's Science Club 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Invited as a guest expert
Year(s) Of Engagement Activity 2013
URL http://www.bbc.co.uk/programmes/b037mkj3
 
Description Stevens - ICiC1 - Fourth International Conference on Multifunctional, Hybrid and Nanomaterials 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The main objective of this large interdisciplinary conference is to bring together, at a truly international level, people with shared interests in hybrid materials. Prof Stevens was a featured speaker.
Year(s) Of Engagement Activity 2015
URL http://www.materialstoday.com/polymers-soft-materials/events/hybrid-materials-2015-/
 
Description Stevens - ICiC1 - HG 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact HG delivered the following oral presentation: Quantum dot-based detection of a tuberculosis-specific transcript signature, Materials Research Society Spring Meeting, San Francisco (April 2015)
Year(s) Of Engagement Activity 2015
URL http://epub.knepperpress.com/publication/index.php?i=249474&m=0&l=&p=318&pre=&ver=html5
 
Description Stevens - ICiC1 - Kavli Nanoscience Symposium, Tondheim 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The Kavli Prizes are awarded biannually in Oslo within the fields of Nanoscience, Neuroscience and Astrophysics.
Year(s) Of Engagement Activity 2014
URL https://www.ntnu.edu/physics/kavlis14
 
Description Stevens - ICiC1 - NPL Workshop: Nanoparticle concentration, chemistry and interfaces 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Workshop: Nanoparticle concentration, chemistry and interfaces. This four-day workshop will engage international experts in a lively scientific debate around the measurement of concentration of nanoparticle in media, their chemistry and the nature of critical interfaces. It was attended by member(s) of Prof Stevens group.
Year(s) Of Engagement Activity 2015
URL http://www.npl.co.uk/np-workshop/
 
Description Stevens - ICiC1 - Nanotechnology & Medicines for Tomorrow 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Biomedical Research Victoria (BioMedVic) is the peak body for the organisations that make up this internationally-recognised research community, providing a collective voice for advocacy and a structure for promoting collaboration and innovation.

Representing universities, teaching hospitals, medical research institutes, CSIRO and other research organisations, Biomedical Research Victoria seeks to develop shared vision, long term plans and better links between government, industry and the biomedical community.

Prof Stevens was the plenary speaker at the November 2014 meeting
Year(s) Of Engagement Activity 2014
URL http://biomedvic.org.au/symposium/nanotechnology-and-medicines-for-tomorrow/
 
Description Stevens - PS2142_MMRE - MRSUS 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation keynote/invited speaker
Geographic Reach International
Primary Audience Other audiences
Results and Impact Over 6000 attended the 2014 MRS Spring Meeting, thus making it hugely successful. The presentations and discussions of materials science and their impact in healthcare applications were very exciting and spurred numerous collaborations and new projects. Prof Stevens was interviewed by MRS TV to discuss the exciting scientific talks and atmosphere present at the meeting, where several Stevens Group members also presented their work.

The MRS Meetings are an excellent source for materials-based research scientists to present their latest results and network with peers to strengthen their research directions and possibilities. This Spring Meeting was an incredible display of the level of research currently ongoing in our fields
Year(s) Of Engagement Activity 2014,2015
URL http://www.mrs.org/spring2014/
 
Description Taylor-Robinson - ICiC1 - AMMF 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact AMMF held a research update event at Imperial College in Feb 2015. 200 members of the public attended an open day at Imperial College London with a series of lectures on our research and the opportunities to ask questions in a "Question Time" debate
Year(s) Of Engagement Activity 2015
URL http://www.ammf.org.uk/2015/03/16/ammf-at-imperial-college-11-03-15/
 
Description Wigneshweraraj - ICiC1 - RNA Polymerase Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact The Annual RNA Polymerase Workshop, hosted by David Grainger and David Lee, came to the University of Birmingham last week. The workshop ran over two days and featured 22 talks across four sessions. The overall focus of the meeting was the mechanism and regulation of transcription.
Year(s) Of Engagement Activity 2014
URL http://imibirmingham.com/2015/05/13/an-overview-of-the-27th-uk-rna-polymerase-workshop-2/